Showing 1261-1270 of 2853 results for "".
- UCSF Professor Bruce Ovbiagele, MD Recognized with Scientific Breakthrough Award at AAN 2024https://practicalneurology.com/news/ucsf-professor-bruce-ovbiagele-md-recognized-with-scientific-breakthrough-award-at-aan-2024/2470442/This year, the American Brain Foundation (ABF) awarded Bruce Ovbiagele, MD, MAS, FAAN the annual Scientific Breakthrough Award. Dr Ovbiagele, a Professor of Neurology at University of California (UC) San Francisco and Associate Dean of the San Francisco Veterans Affairs (VA) Healthcare Syste
- Oral Edaravone Well-Tolerated as ALS Therapyhttps://practicalneurology.com/news/oral-edaravone-well-tolerated-as-als-therapy/2470134/Oral e
- Enhanced Kisunla Dosing Regimen Reduced ARIA-E Risk While Maintaining Amyloid Reduction in Early Alzheimer Diseasehttps://practicalneurology.com/news/enhanced-kisunla-dosing-regimen-reduces-aria-e-risk-while-maintaining-amyloid-reduction-in-early-alzheimer-disease/2470624/Results from the multicenter, randomized, double-blind, phase 3b TRAILBLAZER-ALZ 6 (NCT05738486) clinical trial revealed that an enhanced dosing regimen for Kisunla (donanemab; Eli Lilly and Company, Indianapolis, IN) significantly reduces the frequency and severity of amyloid-related imaging abn
- Evrysdi Therapy for Type 1 Spinal Muscular Atrophy Associated with Favorable 5-Year S&E Datahttps://practicalneurology.com/news/evrysdi-therapy-for-type-1-spinal-muscular-atrophy-associated-with-favorable-5-year-se-data/2470501/Five-year data from the open-label extension of the phase 2 FIREFISH (NCT02913482) clinical trial confirms the sustained efficacy and safety profile of Evrysdi (ridisplam; Genentech, South San Francisco, CA), a treatment for children with Type 1 spinal muscular atrophy (SMA). The results demonstr
- Subcutaneous Lecanemab Shown to Have Similar Efficacy to IV Lecanemab and May Reduce ARIA-Ehttps://practicalneurology.com/news/subcutaneous-lecanemab-shown-to-have-similar-efficacy-to-iv-lecanemab-and-may-reduce-aria-e/2470249/Subcutaneous injection of lecanemab (Eisai, Tokyo, Japan; Biogen, Cambridge, MA) using a vial or autoinjector yielded comparable average steady-state concentrations (Css) to intravenous (IV) administration o
- Possible Treatment for Focal Laryngeal Dystonia Revealed at MDS Conferencehttps://practicalneurology.com/news/possible-treatment-for-focal-laryngeal-dystonia-reported-at-mds-conference/2470597/Results of a double-blind, placebo-controlled, randomized cross-over study presented at the 2024 International Congress of Parkinson’s Disease and Movement Disorders suggest that sodium oxybate (SO) may be an effective treatment for some people with focal laryngeal dystonia (LD). This phase
- In Memoriam: Ralph L. Sacco, MD, MS, FAHA, FAANhttps://practicalneurology.com/news/in-memoriam-ralph-l-sacco-md-ms-faha-faan/2470102/
- Barancik Prize Awarded to Dr. Ruth Ann Marrie at ACTRIMS 2023https://practicalneurology.com/news/barancik-prize-awarded-to-dr-ruth-ann-marrie-at-actrims-2023/2470120/The National Multiple Sclerosis Society announced that Ruth Ann Marrie, MD, P
- Fenfluramine May Usher in Higher Standards for Treatment of Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-may-usher-in-higher-standards-for-treatment-of-dravet-syndrome/2469642/In an editorial in Epilepsy and Behavior, Helen Cross, MD and Joseph Sullivan, MD suggest fenfluramine (Fintepla; Zogenix, Emeryville, CA) clinical trial results can raise the bar for efficacy of antiseizure medications (ASMs) for
- Pitolisant Clinical Trial for Type 1 Myotonic Dystrophy Excessive Daytime Sleepinesshttps://practicalneurology.com/news/pitolisant-clinical-trial-for-type-1-myotonic-dystrophy-excessive-daytime-sleepiness/2469633/A phase 2 clinical trial (NCT04886518) for pitolisant (Wakix; Harmony Biosciences, Plymouth Meeting, PA) in adults with type 1 myotonic dystrophy (DM1) experiencing excessive daytime sleepiness (E